Hepion Pharmaceuticals (NASDAQ: HEPA) sells 61,100,000 shares, warrants
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of equity and warrants. The company agreed to sell 61,100,000 shares of common stock at an offering price of $0.05 per share and issue warrants to purchase 61,100,000 additional shares, for gross proceeds of $3,055,000.
The warrants are exercisable at $0.06 per share for five years from the date of issuance. The agreements include customary representations, warranties, conditions to closing and indemnification obligations between Hepion and the investors. The offering closed on August 3, 2026.
The securities were offered in reliance on exemptions from Securities Act registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D and applicable state laws. As a result, the common stock and warrants issued may not be offered or sold in the United States without registration or an applicable exemption.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 1.01, 3.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares of common stock sold: 61,100,000 shares
Warrants issued: 61,100,000 warrants
Offering price per share: $0.05 per share
+4 more
7 metrics
Shares of common stock sold
61,100,000 shares
Aggregate shares of common stock sold in the private placement Offering
Warrants issued
61,100,000 warrants
Warrants to purchase common stock issued alongside the shares
Offering price per share
$0.05 per share
Price for each share of common stock sold in the Offering
Gross proceeds
$3,055,000
Total gross proceeds to Hepion Pharmaceuticals from the Offering
Warrant exercise price
$0.06 per share
Exercise price for the warrants issued in the transaction
Warrant term
five (5) years
Period during which the warrants are exercisable from issuance
Offering closing date
August 3, 2026
Date on which the private placement Offering closed
Key Terms
private placement offering, accredited investors, warrants, Section 4(a)(2) of the Securities Act, +1 more
5 terms
private placement offering financial
"agreed to sell and issue to the Investors in a private placement offering"
A private placement offering is when a company sells its stock or bonds directly to a small group of investors instead of offering them to the general public. This allows the company to raise money quickly and privately, often for specific projects or needs, without going through a public stock exchange.
accredited investors financial
"entered into securities purchase agreements with certain accredited investors"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
warrants financial
"and warrants to purchase 61,100,000 shares of Common Stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Section 4(a)(2) of the Securities Act regulatory
"offered in reliance upon the exemption from the registration requirement pursuant to Section 4(a)(2)"
A legal exemption that allows a company to sell securities directly to a limited group of buyers without registering the offering with the Securities and Exchange Commission. Think of it like a private sale among known parties rather than a public auction: it can speed fundraising and reduce disclosure requirements, but it also means less public information, lower liquidity and resale restrictions—factors investors should consider when weighing risk and exit options.
Rule 506(b) of Regulation D regulatory
"and/or Rule 506(b) of Regulation D promulgated thereunder"
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What financing transaction did Hepion Pharmaceuticals (HEPA) complete in August 2026?
Hepion Pharmaceuticals completed a private placement, selling 61,100,000 common shares and issuing 61,100,000 warrants. The transaction generated $3,055,000 in gross proceeds and closed on August 3, 2026.
What are the key terms of the warrants issued by Hepion (HEPA)?
Hepion issued warrants to purchase 61,100,000 common shares. The warrants are exercisable at an exercise price of $0.06 per share and have a term of five years from the date of issuance.
How much capital did Hepion Pharmaceuticals (HEPA) raise in this transaction?
Hepion raised $3,055,000 in gross proceeds. This resulted from selling 61,100,000 common shares at $0.05 per share in conjunction with issuing an equal number of warrants in a private placement.
Under which securities law exemptions did Hepion (HEPA) conduct the offering?
The offering relied on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, as well as applicable state securities laws for private placements.
Can the Hepion (HEPA) securities issued in this deal be freely resold in the U.S.?
No. The common stock and warrants issued were not registered under the Securities Act and may not be offered or sold in the United States without registration or an applicable exemption from registration.